Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : N.Y. Jury Delivers $25 Million Judgment Against Johnson & Johnson -- Bloomberg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2019 | 01:27pm EDT

-- A New York jury said Johnson & Johnson (JNJ) must pay $25 million to a woman who claims she got cancer by using the company's products, Bloomberg reports Tuesday.

-- The woman alleged she got a rare type of cancer, linked to asbestos, from some of the company's products which contain talc, the report said.

-- The $25 million is for compensatory damages, and the jury will reconvene next week to consider a punitive penalty, the report said.

-- Johnson & Johnson has denied all allegations its baby powder contained asbestos. The company didn't immediately respond to a request for comment.

www.bloomberg.com/news/articles/2019-05-21/johnson-johnson-loses-25-million-new-york-talc-verdict?utm_source=google&utm_medium=bd&cmpId=google

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

Corrections & Amplifications

This item was corrected at 1:28 p.m. ET to show that a New York jury said Johnson & Johnson (JNJ) must pay a $25 million settlement, not $25 as previously stated in the first paragraph.

This article is part of a news chaine.
Article 1 / 2
<< Preceding Next >>
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:55pJOHNSON & JOHNSON : J&J Offers $4 Billion Opioid Litigation Settlement
DJ
10:57aJohnson & Johnson Shares Rise
DJ
09:04aJOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX for Third Quarter of ..
AQ
02:48aDrug Firms In Talks To Settle Lawsuits -- WSJ
DJ
01:21aJOHNSON & JOHNSON : Wall St gains as reporting season begins
AQ
10/15JOHNSON & JOHNSON : Oklahoma regent resigns over role representing drug maker
AQ
10/15Health-Care Stocks Get a Welcome Respite -- Update
DJ
10/15JOHNSON & JOHNSON : Missouri appeals court overturns $110 million talc verdict
AQ
10/15Drug Distributors in Talks to Settle Opioid Litigation for $18 Billion -- 3rd..
DJ
10/15Drug Distributors in Talks to Settle Opioid Litigation for $18 Billion -- Upd..
DJ
More news
Financials (USD)
Sales 2019 82 236 M
EBIT 2019 25 676 M
Net income 2019 20 112 M
Debt 2019 7 881 M
Yield 2019 2,78%
P/E ratio 2019 19,8x
P/E ratio 2020 18,1x
EV / Sales2019 4,43x
EV / Sales2020 4,16x
Capitalization 357 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 149,21  $
Last Close Price 135,17  $
Spread / Highest target 28,0%
Spread / Average Target 10,4%
Spread / Lowest Target -4,56%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON4.74%350 587
ROCHE HOLDING AG19.25%248 542
MERCK AND COMPANY11.29%217 734
PFIZER-16.38%201 883
NOVARTIS16.20%198 243
AMGEN5.13%122 735